The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
New Jersey’s THC beverage market is heading into the most consequential stretch of its short…
Mormon Wives star Mikayla Matthews says medical cannabis was “literally life-changing” for her nerve pain…
Chains reorder every two weeks and earn twice the discounts. Independents stock the same breadth…
We head to Canna Country Farms in Humboldt for Legendary Strains to discover the Ocimene…
Cannabis advocates should take the lesson here too. The industry doesn't need to inflate its…
Twenty patient associations from across northeastern Brazil are meeting in Fortaleza this month, inside a…